Archive for the 'Lymphoma / Leukemia' Category
Lenalidomide Is Safe And Active: International Study Of Non-Hodgkin Lymphoma
Myron Czuczman, MD, Head, Lymphoma/Myeloma Section, Department of Medicine at Roswell Park Cancer Institute, will present the preliminary results of an international study of lenalidomide (Revlimid®) in patients with relapsed/refractory (r/r) aggressive non-Hodgkin lymphoma (NHL), June 1, at 9 am, at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO), in Chicago, IL.Original post by Diabetes Mine
No commentsAdding Epratuzumab To Standard Chemotherapy
Adding a second monoclonal antibody drug to chemotherapy looks promising for treatment of diffuse large B-cell lymphoma, according to Mayo Clinic researchers working with the North Central Cancer Treatment Group (NCCTG) (http://ncctg.mayo.edu/). Results of this interim analysis are released as part of the 44th Annual Meeting of the American Society of Clinical Oncology.Original post by Diabetes Mine
No commentsExpanding Natural Killer Cells In Cord Blood To Fight Leukemia
Researchers from The University of Texas M. D. Anderson Cancer Center have found a therapy that effectively kills human leukemia cells in mice using natural killer (NK) cells from umbilical cord blood.Patrick Zweidler-McKay, M.D., Ph.D., assistant professor of pediatrics from the Children’s Cancer Hospital at M. D.Original post by Diabetes Mine
No commentsNew Drug Combination Brings 1-2 Punch Against Acute Leukemia
Researchers at The University of Texas M. D. Anderson Cancer Center have discovered a drug combination that kills leukemia cells by shutting down their energy source and hastening cell starvation.In a preclinical study, Lauren Akers, D.O., postdoctoral fellow from the Children’s Cancer Hospital at M. D.Original post by Diabetes Mine
No comments‘Don’t Put Off Visiting Your GP’ Says Cancer Charity, UK
Despite lymphoma being the 6th most common cancer in the UK, nearly 40% of people diagnosed with lymphatic cancer delayed visiting their GP after showing initial symptoms. Recent research has been carried out by the Lymphoma Association to mark Lymphatic Cancer Awareness Week (10-17 May 2008). This patient-based study confirmed the charity’s opinion that awareness of the symptoms of lymphoma are low, meaning that people showing these symptoms may put off a visit to their doctor.Original post by Diabetes Mine
No commentsLeukemia-Initiating Cells Attacked By Arsenic-Based Therapy
In both leukemia and solid tumors, there exists among the multitude of warrior cancer cells a small subgroup that work undercover, patiently lying in wait to launch their attacks. Known as either cancer initiating cells (CICs) or leukemia initiating cells (LICs), these stealth populations are impervious to conventional chemotherapy and undaunted by targeted cancer therapies.Original post by Diabetes Mine
No commentsScottish Medicines Consortium Rules Against Breakthrough Treatment For Devastating Blood Cancer
Celgene Limited expressed disappointment at the advice given by the Scottish Medicines Consortium (SMC) that Revlimid® (lenalidomide) is not recommended for use within the NHS in Scotland for the treatment of multiple myeloma, on the grounds of cost effectiveness. It is estimated that, on average patients, in desperate need of treatment, could gain nearly 3 additional years of life when treated with Revlimid compared with previous standards of care.Original post by Diabetes Mine
No commentsVion Pharmaceuticals Announces Initiation Of Clinical Trial Of Cloretazine(R) (VNP40101M) In Combination With Cytarabine
VION PHARMACEUTICALS, INC. (Nasdaq: VION) announced the start of an investigator-sponsored Phase I/II clinical trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in combination with cytarabine in elderly patients with previously untreated acute myelogenous leukemia (AML) and high-risk myelodysplastic syndromes (MDS). The trial is being conducted under the direction of Ellen K. Ritchie, M.D. at The Weill-Cornell Medical College in New York City.Original post by Diabetes Notes
No commentsRisk Of Leukemia Relapse May Be Revealed By Molecular Change
Researchers may have discovered a better way to distinguish acute leukemia patients who require aggressive treatment to prevent recurrence from those who need only standard therapy for cure.The study is published in the May 1 issue of the New England Journal of Medicine with an accompanying editorial.Original post by Annetics
No commentsNew Analysis Finds Day Care Attendance Early In Life Cuts Childhood Leukaemia Risk By About 30%
Children who attend day care or play groups have about a 30% lower risk of developing the most common type of childhood leukaemia than those who do not, according to a new analysis of studies investigating the link.Original post by Diabetes Notes
No comments